PURPOSE: To make a patient- and treatment-specific computed tomography (CT) scan and to create a three-dimensional (3D) patient model for superficial hyperthermia treatment planning (SHTP). PATIENTS, MATERIALS, AND METHODS: Patients with recurrent breast adenocarcinoma in previously irradiated areas referred for radiotherapy (RT) and hyperthermia (HT) treatment and giving informed consent were included. After insertion of the thermometry catheters in the treatment area, a CT scan in the treatment position was made. RESULTS: A total of 26 patients have been, thus far, included in the study. During the study period, five types of adjustments were made to the procedure: (1) marking the RT field with radioopaque markers, (2) making the CT scan after the first HT treatment instead of before, (3) using an air- and foam-filled (dummy) water bolus, (4) a change to radiolucent catheters for which radioopaque markers were needed, and (5) marking the visible/palpable extent of the tumor with radioopaque markers, if necessary. With these adjustments, all necessary information is visible on the CT scan. Each CT slice was automatically segmented into muscle, fat, bone, and air. RT field, catheters, applicators, and tumor lesions, if indicated, were outlined manually using the segmentation program iSeg. Next the model was imported into SEMCAD X, a 3D electromagnetic field simulator. CONCLUSION: Using the final procedure to obtain a patient- and treatment-specific CT scan, it is possible to create a 3D model for SHTP.
PURPOSE: To make a patient- and treatment-specific computed tomography (CT) scan and to create a three-dimensional (3D) patient model for superficial hyperthermia treatment planning (SHTP). PATIENTS, MATERIALS, AND METHODS: Patients with recurrent breast adenocarcinoma in previously irradiated areas referred for radiotherapy (RT) and hyperthermia (HT) treatment and giving informed consent were included. After insertion of the thermometry catheters in the treatment area, a CT scan in the treatment position was made. RESULTS: A total of 26 patients have been, thus far, included in the study. During the study period, five types of adjustments were made to the procedure: (1) marking the RT field with radioopaque markers, (2) making the CT scan after the first HT treatment instead of before, (3) using an air- and foam-filled (dummy) water bolus, (4) a change to radiolucent catheters for which radioopaque markers were needed, and (5) marking the visible/palpable extent of the tumor with radioopaque markers, if necessary. With these adjustments, all necessary information is visible on the CT scan. Each CT slice was automatically segmented into muscle, fat, bone, and air. RT field, catheters, applicators, and tumor lesions, if indicated, were outlined manually using the segmentation program iSeg. Next the model was imported into SEMCAD X, a 3D electromagnetic field simulator. CONCLUSION: Using the final procedure to obtain a patient- and treatment-specific CT scan, it is possible to create a 3D model for SHTP.
Authors: P Wust; H Stahl; K Dieckmann; S Scheller; J Löffel; H Riess; J Bier; V Jahnke; R Felix Journal: Int J Radiat Oncol Biol Phys Date: 1996-02-01 Impact factor: 7.038
Authors: M M Paulides; J F Bakker; M Linthorst; J van der Zee; Z Rijnen; E Neufeld; P M T Pattynama; P P Jansen; P C Levendag; G C van Rhoon Journal: Phys Med Biol Date: 2010-04-06 Impact factor: 3.609
Authors: H K Lee; A G Antell; C A Perez; W L Straube; G Ramachandran; R J Myerson; B Emami; E P Molmenti; A Buckner; M A Lockett Journal: Int J Radiat Oncol Biol Phys Date: 1998-01-15 Impact factor: 7.038
Authors: J van der Zee; J N Peer-Valstar; P J Rietveld; L de Graaf-Strukowska; G C van Rhoon Journal: Int J Radiat Oncol Biol Phys Date: 1998-03-15 Impact factor: 7.038
Authors: Edwin van der Wal; Martine Franckena; Dennis H M Wielheesen; Jacoba van der Zee; Gerard C van Rhoon Journal: Int J Hyperthermia Date: 2008-12 Impact factor: 3.914
Authors: J Overgaard; D Gonzalez Gonzalez; M C Hulshof; G Arcangeli; O Dahl; O Mella; S M Bentzen Journal: Lancet Date: 1995-03-04 Impact factor: 79.321
Authors: Yasser Abo-Madyan; Martin Polednik; Angelika Rahn; Frank Schneider; Barbara Dobler; Frederik Wenz; Frank Lohr Journal: Strahlenther Onkol Date: 2008-02 Impact factor: 3.621
Authors: M Linthorst; A N van Geel; E A Baartman; S B Oei; W Ghidey; G C van Rhoon; J van der Zee Journal: Strahlenther Onkol Date: 2013-04-04 Impact factor: 3.621
Authors: René F Verhaart; Zef Rijnen; Valerio Fortunati; Gerda M Verduijn; Theo van Walsum; Jifke F Veenland; Margarethus M Paulides Journal: Strahlenther Onkol Date: 2014-11 Impact factor: 3.621